Orshe

Also: Most C-sections performed before labor starts; American companies push into Chinese electronic medical record market; investigators looking at health-care credit cards.

Read more:  A.M. Vitals: Genzyme Points to MS Drug As Sign Sanofi Bid is Too Low

Public hospitals are being sold amidst a general boom in hospital M&A activity.

See the rest here: Public Hospitals, ‘Poorly Equipped to Survive,’ Are Being Sold

Will the Pope sign off on a private-equity deal?

Original post:  Hail Mary Pass? Group Asks Pope to Block Hospital Sale to Cerberus

Pfizer CFO said on an earnings call with analysts that his company is looking for acquisitions worth between a few billion to several billion dollars.

Read the original:  Genzyme and Pfizer, Kissin’ in a Tree? Probably Not.

Merck isn’t ruling out making outright purchases of emerging-market companies, but competition is fierce.

More:  Merck Ready to Play Let’s Make an (Emerging Markets) Deal

Students in the Humanities and Medicine Program get spots in med school as long as they meet certain requirements — but don’t take the usual pre-med pre-requisites.

Read the original here:  Mt. Sinai Program Lets Some Pre-Meds Swap Orgo for Shakespeare

Genzyme’s shares have been battered by its manufacturing woes.

Read the original:  Sanofi-Aventis Sidles Up to Genzyme With ‘Informal Approach,’ WSJ Reports

The cuts are necessary to achieve the projected $3.5 billion in savings the company promised as part of its purchase of Schering-Plough.

View post:  Merck Will Scrap 8 Research, 8 Manufacturing Facilities

The Bloomberg report sent shares of Biogen Idec, Genzyme and Allergan higher.

Read the original post: Report: Sanofi-Aventis Readying Large U.S. Acquisition

Also: a $1.3 billion health IT merger; abortion-inducing pills via telemedicine in Iowa.

Read the original:  A.M. Vitals: Novartis Drug Safety Questions; ‘Doc Fix’ Coming?